TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A roundup published October 20, 2026, summarized endocrinology research and industry developments. It reported that roughly one-quarter of active-duty U.S. Army men had a single morning testosterone reading below 300 ng/dL, while separate items covered menopause symptoms, GLP-1 medicines and side-effect terms in Reddit posts about unapproved retatrutide. The findings have different evidence bases and do not establish diagnoses or prove that reported effects were caused by the drugs.
An endocrinology roundup published October 20 reported that roughly one-quarter of active-duty U.S. Army men had a single morning testosterone concentration below 300 ng/dL, a commonly used cutoff for low testosterone. The same report summarized U.S. menopause data and an analysis of Reddit posts about side effects associated with the unapproved weight-loss drug retatrutide; those findings describe different populations and types of evidence, and do not establish individual diagnoses or drug causation.
The Army finding was attributed to a study in JAMA. The measure was a single morning testosterone concentration, not a diagnosis based on repeated tests or an assessment of symptoms. The source report did not provide the study’s sample size, the exact percentage, or further details about how participants were selected.
A separate CDC report found that nearly half of U.S. women ages 40 to 60 reported menopausal symptoms in 2025. Of that group, 15.6% said they were taking prescription medication for those symptoms. The roundup also reported that Novo Nordisk said a post-hoc analysis of a phase III trial found an average 25% weight loss among women using its investigational semaglutide-cagrilintide combination, with similar results across pre-, peri- and postmenopausal stages.
For retatrutide, researchers analyzed Reddit posts from users reporting use of the unapproved drug. Commonly cited adverse-event terms included appetite increases, fatigue, increased energy, insomnia, faster heart rate and muscle-related symptoms, according to the summary of a study in JAMA Network Open. Social-media reports can identify experiences people discuss, but cannot by themselves verify diagnoses, exposure or whether a medicine caused a symptom.
Different Evidence, Different Implications
The findings concern issues relevant to military health, menopause care and weight-loss medicines, but they should not be read as interchangeable measures of risk or disease. A low result from one testosterone test is a screening observation; the roundup does not say that one in four soldiers has a confirmed clinical condition or requires treatment.
The menopause figures offer a measure of how commonly symptoms were reported and how many women in the specified age group used prescription treatment. The retatrutide analysis adds information about what people are discussing online, not a controlled estimate of how often side effects occur. For readers weighing treatment decisions, that distinction matters: online reports are not a substitute for clinical trial safety data, and the drug discussed is unapproved.
Products Worth Considering
Therabody Theragun Relief Massage Gun, 3-Speed, Black
Bowflex SelectTech 840 Adjustable Kettlebell
Oura Ring 5 Smart Ring, Silver, Size 7
As an affiliate, we earn on qualifying purchases.
The Broader Endocrinology Roundup
The report was a short roundup of research and business developments, rather than one study focused on a single condition. It also cited National Health Interview Survey findings that one in six adults with type 1 diabetes reported moderate to severe depression or anxiety symptoms, published in Annals of Internal Medicine.
Other items included a meta-analysis of phase III trial data linking greater weight reduction from GLP-1 receptor agonists and emerging multi-hormone receptor modulators with larger blood-pressure reductions. Early research on possible anti-aging effects was also mentioned, but the source characterized that work as preliminary. The roundup further noted Walmart’s plan to cover more than 250 prescription drugs at no cost for employees in 2027, including some insulins and diabetes GLP-1 drugs, and a research collaboration focused on protein-based therapies for obesity and metabolic disease.
“Nearly half of American women ages 40 to 60 reported menopausal symptoms in 2025.”
— The CDC report, as summarized by MedPage Today
Limits of the Available Findings
The roundup does not supply enough detail to assess the Army study’s methods, participant count, or how many men had repeat testing or symptoms. A single reading below 300 ng/dL does not, on the information provided, establish a diagnosis. The menopause summary likewise does not give the full survey methodology or explain which prescription medicines respondents used.
For retatrutide, the source does not state how many Reddit posts or users were analyzed, how reports were verified, or whether symptoms were medically assessed. The listed terms should not be treated as confirmed adverse reactions or as estimates of their frequency among people taking the drug. The exact study results and trial details behind the other summarized claims are also not included in the supplied report.
Further Study and Trial Details
Readers seeking a fuller assessment will need the underlying studies, including their methods, sample sizes and limitations, rather than the brief roundup alone. Further clinical research would be needed to determine how often the reported testosterone readings persist and how social-media accounts of retatrutide use compare with systematically collected safety data.
The source gives no timetable for new findings on these topics. It does say Walmart’s employee drug coverage plan is scheduled for 2027; the timing and scope of further research or regulatory developments for the investigational treatments remain unspecified.
Key Questions
Does the Army finding mean one in four soldiers has a confirmed low-testosterone diagnosis?
No. The report describes a single morning reading below 300 ng/dL, a commonly used cutoff. It does not say that every person with such a reading had a confirmed diagnosis based on repeat tests or symptoms.
What did the menopause data report?
Nearly half of U.S. women ages 40 to 60 reported symptoms in 2025. Among that group, 15.6% reported using prescription medication for those symptoms, according to the CDC report summarized in the roundup.
Do the Reddit posts prove retatrutide caused the symptoms listed?
No. The analysis identified commonly used adverse-event terms in posts by people reporting use of unapproved retatrutide. Online accounts cannot establish that a drug caused a symptom or show how frequently it occurs.
Was the reported semaglutide-cagrilintide result from a menopause-specific trial?
The roundup describes it as a post-hoc analysis of a phase III trial reported by Novo Nordisk, with similar results across pre-, peri- and postmenopausal stages. The supplied summary does not provide further trial details.
Source: rss
